Title
Mapping of a gene determining tuberous sclerosis to human chromosome 11q14-11q23.

Permalink
https://escholarship.org/uc/item/0fv7d9cp

Journal
Genomics, 6(1)

ISSN
0888-7543

Authors
Smith, M
Smalley, S
Cantor, R
et al.

Publication Date
1990

DOI
10.1016/0888-7543(90)90454-3

License
CC BY 4.0

Peer reviewed
Mapping of a Gene Determining Tuberous Sclerosis to Human Chromosome 11q14–11q23


*University of California, Irvine, California 92717; †Neuropsychiatry Institute, UCLA School of Medicine, Los Angeles, California 90024; ‡Mayo Clinic, Rochester, Minnesota 55905; §Howard Hughes Medical Institute, Salt Lake City, Utah 84132; †Neurogenetics Division, Massachusetts General Hospital, Boston, Massachusetts 02114; #Department of Human Genetics, Indiana University, Bloomington, Indiana 47401; and ‡College of Physicians and Surgeons, Columbia University, New York, New York 10027

Received May 8, 1989; revised August 20, 1989

INTRODUCTION

Tuberous sclerosis (TSC) is a dominantly inherited disorder characterized by hamartomas and hamartias in one or more organs, most often the skin, brain, and kidneys. Analysis of the basic genetic defect in tuberous sclerosis would be greatly expedited by definitive determination of the chromosomal location of the TSC gene or genes. We have carried out genetic linkage studies in 15 TSC families, using 34 polymorphic markers including protein markers and DNA markers. Pairwise lod scores were calculated using LIPED, and multipoint analyses were carried out using MENDEL. In the pairwise linkage analysis, using a penetrance value of 90%, a significant positive lod score was obtained with MCT128.1 (D11S144), 11q22-11q23, Zmax 3.28 at θ = 0.08. The tyrosinase probe TYR (11q14–11q22) gave a maximum lod score of 2.88 at θ = 0. The tyrosinase probe TYR (11q14–11q22) gave a maximum lod score of 2.88 at θ = 0. In the multipoint analyses the most likely order is (TYR, TSC)–MCT128.1–HHH172. Homogeneity analysis was carried out using the USERMS subprogram of MENDEL, which conducts the admixture test of C. Smith (1963, Ann. Hum. Genet. 27: 175–182). This test provided no evidence for genetic heterogeneity (that is, non-11-linked families) in this data set.

© 1990 Academic Press, Inc.

Although TSC is known to be inherited as an autosomal dominant mutation, a large percentage of cases are thought to represent new mutations, since manifestations occur in children whose parents show no manifestations of the disorder. However, unaffected parents may have more than one affected child. It is not clear whether such cases represent examples of gonadal mosaicism or reduced penetrance in one of the parents (Baraitser and Patton, 1985). The population frequency of tuberous sclerosis was estimated by Wiederholt et al. (1985) as 1 in 10,000. Estimations of the frequency of new mutations have varied from 1 in 60,000 (Gunther and Penrose, 1935) to 1 in 84,000 live births (Singer, 1971). Accurate assessments of the percentage of cases that represent new mutations and of the degree of penetrance of TSC are not realistic at this time, given the limitations of clinical examination, CT scans, and magnetic resonance imaging. Considerable variation in severity of
TSC may be encountered among affected members of a particular family, providing evidence of variable expressivity.

Analysis of the basic genetic defect in tuberous sclerosis would be greatly expedited by definitive determination of the chromosomal location of the TSC gene or genes. Fryer et al. (1987) published evidence for location of a TSC gene on chromosome 9q34, based on a peak cumulative lod score of 3.85 at $\theta = 0$, between TSC and ABO. Connor et al. (1987a,b) reported linkage between TSC and another chromosome 9q34 marker ABL in three Scottish families. The maximum lod score
was 3.18 at $\theta = 0$. Subsequently, there have been reports of families for which data analysis did not support linkage between TSC and ABO (Northrup et al., 1987; Renwick, 1987). Povey et al. (1988) published evidence for recombination between TSC and ABL in two families. Kandt et al. (1989) carried out two-point and multilocus linkage analyses of TSC and three chromosome 9q markers: ABO, MCT136, and ABLK2.
These analyses allowed them to exclude TSC for a distance of 20 cM adjacent to the ABO locus. Results of their two-point and multipoint data were subjected to analysis using the HOMOG program of Ott (1974). There was insufficient evidence for rejection of the null hypothesis of homogeneity.

In this paper we describe results of linkage analysis carried out in 15 families with tuberous sclerosis, using 34 polymorphic markers, including protein markers and DNA markers.

**MATERIALS AND METHODS**

**TSC Families Studied**

A total of 15 families were analyzed. These included one 5-generation, three 4-generation, eight 3-generation, and three 2-generation families. Data are derived from 150 individuals. Documentation of the pedigrees of families analyzed in this study is provided in Fig. 1. The clinical manifestations in the affected individuals are documented on the pedigrees. An explanation of the abbreviations used is provided in the legend to Fig. 1.

**Sample Collection and Derivation of Cell Lines**

Blood samples were collected in ACD B tubes and in heparin tubes. Heparinized blood was used for isolation of plasma and red cells for analysis of blood groups, plasma protein markers, and red cell enzyme markers. Blood collected in ACD was used for isolation of peripheral blood lymphocytes by means of Ficoll-Paque (Pharmacia) density gradient centrifugation. The lymphocyte sample was used for direct preparation of DNA. In 9 of the 15 families lymphoblastoid cell lines were established by seeding lymphocytes, at a concentration of approximately 2 million cells/ml, in RPMI 1640 medium containing 10% fetal calf serum, 2 µg/ml cyclosporin, and Epstein–Barr virus. The virus was present in filtered frozen medium derived from a marmoset cell line which carries the virus. This medium was added at a concentration of 10%.

**Preparation of Genomic DNA**

Pellets of peripheral blood lymphocytes or lymphoblastoid cell lines were resuspended in lysis buffer containing 10 mM Tris–HCl, pH 8.0, 50 mM EDTA, 0.2% SDS (ultra pure sodium dodecyl sulfate, Sigma). They were then digested using 50 µg/ml proteinase K for 4
TUBEROUS SCLEROSIS GENE MAPPING

TABLE 1

<table>
<thead>
<tr>
<th>Marker/locus</th>
<th>Chromosomal location</th>
<th>Ref.</th>
<th>0.05</th>
<th>0.10</th>
<th>0.20</th>
<th>0.30</th>
<th>0.40</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rh</td>
<td>1p36</td>
<td>(34)</td>
<td>-4.07</td>
<td>-2.44</td>
<td>-0.99</td>
<td>-0.42</td>
<td>-0.15</td>
</tr>
<tr>
<td>PGMI</td>
<td>1p22.1</td>
<td>(6)</td>
<td>-3.47</td>
<td>-2.13</td>
<td>-0.96</td>
<td>-0.42</td>
<td>-0.14</td>
</tr>
<tr>
<td>FY</td>
<td>1p12-q23</td>
<td>(48)</td>
<td>-3.28</td>
<td>-1.06</td>
<td>0.98</td>
<td>0.75</td>
<td>0.43</td>
</tr>
<tr>
<td>JK</td>
<td>2p</td>
<td>(48)</td>
<td>-3.96</td>
<td>-1.45</td>
<td>-0.57</td>
<td>-0.67</td>
<td>-0.15</td>
</tr>
<tr>
<td>TGFA*</td>
<td>2p13</td>
<td>(3)</td>
<td>-2.07</td>
<td>-1.09</td>
<td>-0.26</td>
<td>-0.01</td>
<td>0.09</td>
</tr>
<tr>
<td>ACPI</td>
<td>2p25</td>
<td>(27)</td>
<td>-3.23</td>
<td>-5.14</td>
<td>-2.33</td>
<td>-0.99</td>
<td>-0.29</td>
</tr>
<tr>
<td>PDF164.2* (D3S46)</td>
<td>3</td>
<td>(37)</td>
<td>-1.18</td>
<td>-0.67</td>
<td>-0.25</td>
<td>-0.09</td>
<td>-0.02</td>
</tr>
<tr>
<td>pHMG*</td>
<td>4p11-q21</td>
<td>(47)</td>
<td>-0.54</td>
<td>0.11</td>
<td>0.45</td>
<td>0.37</td>
<td>0.14</td>
</tr>
<tr>
<td>pF47*</td>
<td>4p11-q21</td>
<td>(36)</td>
<td>-1.44</td>
<td>-0.89</td>
<td>-0.39</td>
<td>-0.15</td>
<td>-0.03</td>
</tr>
<tr>
<td>pEGF121*</td>
<td>4q21-q25</td>
<td>(36)</td>
<td>-0.72</td>
<td>-0.44</td>
<td>-0.19</td>
<td>-0.08</td>
<td>-0.02</td>
</tr>
<tr>
<td>PADH74 and 36*</td>
<td>4q21-q25</td>
<td>(36)</td>
<td>-4.70</td>
<td>-2.61</td>
<td>-0.90</td>
<td>-0.24</td>
<td>-0.10</td>
</tr>
<tr>
<td>GC</td>
<td>4q21</td>
<td>(38,12)</td>
<td>-1.95</td>
<td>-0.88</td>
<td>-0.14</td>
<td>0.09</td>
<td>0.10</td>
</tr>
<tr>
<td>HHH171* (D6S38)</td>
<td>6p</td>
<td>(24)</td>
<td>-2.18</td>
<td>-1.37</td>
<td>-0.65</td>
<td>-0.31</td>
<td>-0.12</td>
</tr>
<tr>
<td>BF</td>
<td>6p21</td>
<td>(41)</td>
<td>-2.05</td>
<td>-1.23</td>
<td>-0.51</td>
<td>-0.18</td>
<td>-0.04</td>
</tr>
<tr>
<td>GLO</td>
<td>6p21</td>
<td>(32)</td>
<td>4.14</td>
<td>2.72</td>
<td>1.49</td>
<td>0.97</td>
<td>1.14</td>
</tr>
<tr>
<td>HH172 (D8S38)</td>
<td>6p</td>
<td>(15)</td>
<td>0.01</td>
<td>0.00</td>
<td>-0.01</td>
<td>-0.01</td>
<td>-0.02</td>
</tr>
<tr>
<td>PSW50*</td>
<td>8p23</td>
<td>(59)</td>
<td>-0.72</td>
<td>-0.44</td>
<td>-0.20</td>
<td>-0.07</td>
<td>-0.02</td>
</tr>
<tr>
<td>ESF</td>
<td>13q14</td>
<td>(53)</td>
<td>-0.86</td>
<td>-0.54</td>
<td>-0.23</td>
<td>-0.08</td>
<td>-0.01</td>
</tr>
<tr>
<td>pAW101*</td>
<td>14q13</td>
<td>(11)</td>
<td>-2.51</td>
<td>-1.18</td>
<td>-0.67</td>
<td>-0.95</td>
<td>-0.09</td>
</tr>
<tr>
<td>HP</td>
<td>16q22</td>
<td>(35)</td>
<td>-3.38</td>
<td>-2.73</td>
<td>-0.86</td>
<td>-0.33</td>
<td>-0.08</td>
</tr>
<tr>
<td>Alphoid*</td>
<td>17cen</td>
<td>(26)</td>
<td>-0.46</td>
<td>-0.23</td>
<td>-0.06</td>
<td>-0.01</td>
<td>0.00</td>
</tr>
<tr>
<td>ADA</td>
<td>20q13</td>
<td>(23)</td>
<td>0.32</td>
<td>0.33</td>
<td>0.30</td>
<td>0.24</td>
<td>0.14</td>
</tr>
<tr>
<td>pMSI-27* (D20S4)</td>
<td>20</td>
<td>(18,25)</td>
<td>-0.46</td>
<td>-0.23</td>
<td>-0.06</td>
<td>-0.01</td>
<td>0.00</td>
</tr>
</tbody>
</table>

* RFLP marker.

Marker at 37°C. Following digestion, DNA was extracted from these solutions by using phenol–chloroform, according to the method described by Maniatis et al. (1982).

Markers Analyzed

We analyzed 34 polymorphic markers, including 13 serum protein and red cell markers and 21 polymorphic DNA markers. The markers analyzed are distributed on 13 of the 22 human autosomes. Not all families were analyzed for each marker. Fourteen families were analyzed for the chromosome 9q markers, and 10 families were analyzed for the chromosome 11q markers. The difference in the number of families analyzed is because DNA supplies were depleted prior to commencement of certain of the analyses, where lymphoblastoid cell lines were not established. The markers analyzed are listed in Tables 1, 2, and 3. Methods used for characterization of markers are referenced in the tables.

The chromosome 11 probes MCT128.1, C1J52.208M2, HHH172, HBI18P1, and HBI18P2 were provided by Drs. Y. Nakamura and C. Julier. These latter probes are random DNA probes that have been assigned to the distal half of chromosome 11q (Nakamura and Julier, personal communication; Junien and McBride, 1989). The probe for tyrosinase, pMel 34-1, was provided by Dr. B. Kwon (Kwon et al., 1987).

Linkage Analysis

The two-point linkage data were analyzed used the program LIPED (Ott, 1985). In order to facilitate data entry into the LIPED system, the LIPIN program (Trofatter et al., 1986) was used. Since there is clear evidence that some individuals who may carry the TSC gene have no clinical manifestations and may also have negative findings in special examinations such as head CT scan, abdominal ultrasound, and X-ray, it is important that a penetrance factor less than 100% be included in the linkage calculations. In the two-point linkage analysis, lod scores were computed in two ways: first, setting the penetrance at 90%; and second, setting the penetrance at 97%. In the first model we postulate that an individual has a 90% conditional probability of being affected given that he has a copy of the TSC gene. In the second model an individual has a 97% conditional probability of being affected given that he has a copy of the TSC gene. The 90% penetrance value was initially selected on the basis of information on TSC cases accumulated by Dr. K. Dumars at the University of California, Irvine. Analysis was subsequently
TABLE 2
(a) Results of Pairwise Linkage Analysis of TSC and Chromosome 9q34 Markers Using a 90% Penetrance Rate of TSC

<table>
<thead>
<tr>
<th>Locus</th>
<th>0.00</th>
<th>0.05</th>
<th>0.10</th>
<th>0.15</th>
<th>0.20</th>
<th>0.30</th>
<th>0.40</th>
<th>Families</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABO</td>
<td>-∞</td>
<td>-4.35</td>
<td>-2.27</td>
<td>-1.07</td>
<td>-0.46</td>
<td>-0.08</td>
<td>0.14</td>
<td>All except 11</td>
</tr>
<tr>
<td>ASSG3</td>
<td>-3.66</td>
<td>-0.21</td>
<td>-0.01</td>
<td>0.06</td>
<td>0.09</td>
<td>0.08</td>
<td>0.05</td>
<td>1,18,96</td>
</tr>
<tr>
<td>AK1</td>
<td>-10.05</td>
<td>-2.89</td>
<td>-1.87</td>
<td>-1.29</td>
<td>-0.91</td>
<td>-0.41</td>
<td>-0.14</td>
<td>8,16</td>
</tr>
<tr>
<td>ABL</td>
<td>-5.16</td>
<td>-0.72</td>
<td>-0.44</td>
<td>-0.29</td>
<td>-0.19</td>
<td>-0.08</td>
<td>-0.02</td>
<td>8</td>
</tr>
</tbody>
</table>

Note. ASSG3 is a probe derived from the ASS gene (40). AK1 was typed using the enzyme polymorphism (21) and a DNA probe (4). ABL was typed using a DNA probe ABL 3 (Baumann and Smith, personal communication).

(b) Allele Frequencies of Chromosome 9 Markers

(i) ABO blood groups

<table>
<thead>
<tr>
<th>Marker</th>
<th>Allele 1</th>
<th>Allele 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>0.2090</td>
<td>0.0696</td>
</tr>
<tr>
<td>B</td>
<td>0.0612</td>
<td>0.6602</td>
</tr>
<tr>
<td>O</td>
<td>0.50</td>
<td>0.50</td>
</tr>
</tbody>
</table>

(ii) DNA markers

<table>
<thead>
<tr>
<th>Marker</th>
<th>Allele 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASSG3</td>
<td>0.50</td>
</tr>
<tr>
<td>AK1</td>
<td>0.79</td>
</tr>
<tr>
<td>ABL</td>
<td>0.20</td>
</tr>
</tbody>
</table>

Note. Allele 1 corresponds to larger molecular weight polymorphic DNA fragment.

RESULTS

Two-Point Linkage Analysis

Linkage analysis between TSC and the 24 marker loci listed in Table 1 provided no evidence of linkage. Results of two-point linkage analysis between TSC and the chromosome 9q34 markers ABO, ABL, ASSG3, and AK1, listed in Table 2, do not support assignment of the TSC gene to this region. Results of two-point linkage analysis between TSC and 6 markers that map to chromosome 11q14-qter (tyrosinase, MCT128.1, CJ52.208M2, HBI18P1, HBI18P2, and HHH172) are listed in Table 3. A significant positive lod score was obtained with the probe MCT128.1 ($Z_{max} = 3.26$ at $\theta$).
TUBEROUS SCLEROSIS GENE MAPPING

TABLE 3
(a) Results of Pairwise Linkage Analysis of TSC and Chromosome 11q Markers
(Penetrance Value for TSC 0.9)

<table>
<thead>
<tr>
<th>Locus</th>
<th>0.00</th>
<th>0.05</th>
<th>0.10</th>
<th>0.15</th>
<th>0.20</th>
<th>0.30</th>
<th>0.40</th>
<th>Families</th>
</tr>
</thead>
<tbody>
<tr>
<td>TYR</td>
<td>2.88</td>
<td>2.58</td>
<td>2.27</td>
<td>1.97</td>
<td>1.64</td>
<td>1.04</td>
<td>0.49</td>
<td>16,21,15</td>
</tr>
<tr>
<td>128.1</td>
<td>-3.25</td>
<td>3.20</td>
<td>3.93</td>
<td>3.66</td>
<td>3.64</td>
<td>3.44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>208M2</td>
<td>-∞</td>
<td>0.91</td>
<td>1.01</td>
<td>0.95</td>
<td>0.84</td>
<td>0.56</td>
<td>0.27</td>
<td>1,3,15,16,8,11,20,21,26</td>
</tr>
<tr>
<td>HHH172</td>
<td>-3.22</td>
<td>0.26</td>
<td>0.56</td>
<td>0.65</td>
<td>0.62</td>
<td>0.40</td>
<td>0.15</td>
<td>21,3,26,11,24,15</td>
</tr>
<tr>
<td>18P1</td>
<td>1.39</td>
<td>1.24</td>
<td>1.09</td>
<td>0.98</td>
<td>0.84</td>
<td>0.68</td>
<td>0.54</td>
<td>21,26</td>
</tr>
<tr>
<td>18P2</td>
<td>-7.02</td>
<td>-0.91</td>
<td>-0.44</td>
<td>-0.21</td>
<td>-0.09</td>
<td>0</td>
<td>0.01</td>
<td>21,11</td>
</tr>
</tbody>
</table>

References for chromosomal assignments:
128.1 or MCT128.1 (D11S144) (28)
208M2 or CJ52.208M2 (D11S351) (28)
H172 or HHH172 (D11S350) (28)
18P2 or HBI18P2 (D11S147) (28)
18P1 or HBI18P1 (Nakamura and Julier, personal communication)
TYR or pMel 34-1 (54)

(b) Allele Frequencies of Chromosome 11 DNA Markers

<table>
<thead>
<tr>
<th>Marker</th>
<th>Allele 1</th>
<th>Allele 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>TYR</td>
<td>0.52</td>
<td>0.48</td>
</tr>
<tr>
<td>128.1</td>
<td>0.52</td>
<td>0.48</td>
</tr>
<tr>
<td>208M2</td>
<td>0.41</td>
<td>0.59</td>
</tr>
<tr>
<td>HHH172</td>
<td>0.60</td>
<td>0.40</td>
</tr>
<tr>
<td>18P1</td>
<td>0.60</td>
<td>0.40</td>
</tr>
<tr>
<td>18P2</td>
<td>0.25</td>
<td>0.75</td>
</tr>
</tbody>
</table>

Note. Allele 1 corresponds to higher molecular weight polymorphic DNA fragment.

Since there are no recombinants between tyrosinase and the disease gene, we cannot differentiate between two of the possible orders of these loci. We observed the largest log likelihood (-128.1) with the TSC locus centromeric to MCT128.1 and HHH172. As the TSC locus is moved away from tyrosinase, we observed a decrease in log likelihoods, as anticipated given the zero recombination observed between tyrosinase and TSC. In these data we find an odds ratio of 63.1 against the location of the TSC locus being telomeric to HHH-172. However, we cannot exclude the possibility of the TSC locus lying between MCT128.1 and HHH172.

Heterogeneity Testing

The USERMS subprogram of MENDEL was run using the three regionally assigned markers on chromosome 11q, TYR, MCT128.1, and HHH172. The maximum likelihood estimate of $\alpha$ for each marker tested is 1, with no difference in the log likelihood or estimates of $\theta_{male}$ and $\theta_{female}$ in each case. No formal test of heterogeneity could be conducted, as $\alpha$ was estimated at 1, the boundary value. We conclude that there is no evidence of genetic heterogeneity in the sample.
DISCUSSION

Results of our studies strongly support the location of a tuberous sclerosis locus on chromosome 11. Our two-point linkage analysis data did not support localization of a TSC gene to human chromosome 9q34 region. The studies of Fryer et al. (1987) and Connor et al. (1987a,b) did not utilize chromosome 11q markers. The assignment of a TSC gene to the vicinity of the tyrosinase gene is of interest in view of the abnormalities of pigmentation seen in this disorder. Tyrosinase in melanocytes is responsible for the conversion of tyrosine to DOPA and of DOPA to the DOPA quinones which give rise to melanin (Witkop et al., 1978). One of the most common abnormalities in TSC is the occurrence of hypomelanotic macules, which may include typical ashleaf spots, large areas of depigmentation, or multiple confetti spots (Gomez, 1988). Cafe au lait spots also occur more frequently in TSC patients than in the normal population. We have noted that hypopigmented macules with darkly pigmented regions at their center occur frequently in TSC patients. In certain patients, white hair patches also occur. Electron microscopic examination of hypomelanotic macules from TSC patients has revealed that the melanosomes within melanocytes are reduced in number and size and in the degree of melanization (Rogers, in Gomez, 1988). It is possible that these pigmentation abnormalities in TSC may be due to the proximity of the TSC gene to the gene encoding tyrosinase.

The assignment of a TSC gene to human chromosome 11 is also of interest in light of two literature reports that describe the simultaneous occurrence of TSC and other genetic disorders. The ataxia telangiectasia gene was recently mapped to the 11q22-11q23 region by Gatti and co-workers (1988). The first report in the literature of increased radiation sensitivity in ataxia telangiectasia involved a patient with this disorder who was found on autopsy to have tuberous sclerosis (Gotoff et al., 1967). TSC has been reported in two patients with features of multiple endocrine neoplasia type 1 (MEN1). The gene responsible for MEN1 was mapped to the chromosome 11q13 region (Bale et al., 1987). It is of interest to note that in reviewing the significance of the cases with TSC and MEN1, Zimmermann (1988; see Gomez, 1988) considered two possibilities: first, that the fullest expression of TSC may include a form of multiple endocrine neoplasia resembling MEN 1; and second, that TSC and MEN1 are genetically linked.

We initiated a study of chromosome 11q markers following the finding of an infant who was the first case of TSC in a family and who had in addition an unbalanced 11/22 chromosomal translocation with a breakpoint in the 11q22-11q23 region (Clark et al., 1988).

Further studies aimed at refining the regional localization of the TSC gene on chromosome 11 are in progress. Refined regional localization will open the way for detailed analysis of the molecular genetic defect in tuberous sclerosis. It will also be important to carry out linkage studies in additional families with TSC to establish whether there is genetic heterogeneity in this disorder. Families who have demonstrated linkage of TSC and chromosome 9q34 region should also be analyzed using a series of chromosome 11q markers. Additional studies should be carried out to exclude the possibility that chromosomal translocations are present in certain TSC families.

ACKNOWLEDGMENTS

We acknowledge the help of a number of clinicians who put us in contact with families with tuberous sclerosis: Dr. Roberta Pagon, University of Washington; Dr. Peter Huttenlocher, University of Chicago; Dr. R. Carnuthers, Nassau County Medical Center; Dr. William Johnson, Columbia University; Dr. Jeff Murray and Dr. Mary Waziri, University of Iowa. We acknowledge the expert technical assistance of Caryn Wagner and Kathy Yoshiyama for cell cultivation and DNA preparation. We thank Dr. B. Kwon for making the tyrosinase gene probe available to us. We are particularly grateful for the advice given to us by Dr. K. Lange in the use of the MENDEL pedigree analysis program. We gratefully acknowledge the encouragement and support of the National Tuberous Sclerosis Association.
Funding for this project was provided by Grant HD23745 to M.S. from the National Institute of Childhood Diseases.

REFERENCES


